---
title: Magnesium Sulfate and Trigger Points
nct_id: NCT06975813
overall_status: NOT_YET_RECRUITING
phase: PHASE2
sponsor: Fayoum University
study_type: INTERVENTIONAL
primary_condition: Myofascial Pain Syndrome
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06975813.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06975813"
ct_last_update_post_date: 2025-05-16
last_seen_at: "2026-05-12T06:08:21.213Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Magnesium Sulfate and Trigger Points

**Official Title:** Efficacy of Isolated Masseter Versus Masseter- Sternocleidomastoid Trigger Points Injection by Magnesium Sulfate for Myofacial Pain

**NCT ID:** [NCT06975813](https://clinicaltrials.gov/study/NCT06975813)

## Key Facts

- **Status:** NOT_YET_RECRUITING
- **Phase:** PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Fayoum University
- **Conditions:** Myofascial Pain Syndrome
- **Start Date:** 2025-06-01
- **Completion Date:** 2026-01-27
- **CT.gov Last Update:** 2025-05-16

## Brief Summary

The patients will be randomly assigned to one of the two groups according to the treatment method: group I (masseter group) and group II (masseter \&sternocleidomastoid group) where each patient will be injected 0.5ml in each trigger point (TrPs) of magnesium sulphate according to the treatment group by the same operator. The treatment method for TrPs will be the primary predictor variable. Patients will be examined at the following intervals: during diagnosis, 1-month, 3-months, and 6-months post-injection. The participated patients will be assessed using pain score measured on a 10-point visual analogue scale (VAS), the 0 indicating no pain and 10 indicating the worst pain ever

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* definite diagnosis of myofascial pain
* presence of one or more unilateral or bilateral trigger points in the masseter muscle and sternocleidomastoid muscle;
* no history of any invasive procedures of the related masseter muscle.

Exclusion Criteria:

* any painful conditions (other than myofascial trigger points) affecting the orofacial region
* any systemic diseases that could masticatory function (e.g., rheumatoid arthritis and epilepsy);
* pregnancy and lactation
```

## Arms

- **masseter muscle** (ACTIVE_COMPARATOR)
- **masseter and sternocleidomastoid muscles** (EXPERIMENTAL)

## Interventions

- **masseter muscle** (DRUG) — masseter muscle trigger points injection by magnesium sulphate
- **masseter and sternocleidomastoid muscle** (DRUG) — masseter and sternocleidomastoid muscle trigger points injection by magnesium sulphate

## Primary Outcomes

- **muscle pain** _(time frame: 6 months)_ — by visual analogue scal

## Recent Field Changes (last 30 days)

- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06975813.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06975813*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*